Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of “Moderate Buy” from Analysts

Qiagen N.V. (NYSE:QGEN) has received an average recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $47.0877.

A number of brokerages have issued reports on QGEN. Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Friday, February 6th. Barclays set a $38.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research note on Wednesday, April 29th. UBS Group set a $52.00 price objective on shares of Qiagen in a research note on Monday, February 9th. Finally, Robert W. Baird set a $43.00 price objective on shares of Qiagen and gave the stock an “outperform” rating in a research note on Wednesday, April 29th.

Institutional Investors Weigh In On Qiagen

Large investors have recently bought and sold shares of the company. Danske Bank A S acquired a new stake in Qiagen during the third quarter worth about $36,000. Smartleaf Asset Management LLC grew its stake in Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after buying an additional 830 shares in the last quarter. Manchester Capital Management LLC acquired a new stake in shares of Qiagen in the 4th quarter valued at approximately $42,000. Global Retirement Partners LLC boosted its stake in shares of Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in shares of Qiagen by 23.2% in the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after purchasing an additional 256 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Trading Up 0.1%

QGEN stock opened at $33.98 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. The company’s 50-day simple moving average is $41.49 and its 200 day simple moving average is $46.61. Qiagen has a 52 week low of $33.17 and a 52 week high of $57.81. The company has a market capitalization of $7.00 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 3.38 and a beta of 0.64.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. Qiagen’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.61 earnings per share. As a group, sell-side analysts anticipate that Qiagen will post 2.44 earnings per share for the current year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.